Across TCGA pan-cancer cohorts, OR5D16 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated OR5D16 data layer compared with 7 for mass-spec protein.
The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher OR5D16 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR5D16 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
DLBC, KIRP, and HNSC are the cancer types where OR5D16 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.